Cencora, Inc.
NYSE•COR
CEO: Mr. Steven H. Collis
板块: Healthcare
行业: Medical - Distribution
上市日期: 1995-04-04
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
联系方式
市值
$69.89B
市盈率 (TTM)
42.9
33.7
股息率
0.6%
52周最高
$377.54
52周最低
$248.59
52周范围
排名13Top 2.2%
6.8
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
强劲 • 6.8 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025
财务仪表盘
Q1 2026 数据
营业收入
$85.93B+0.00%
近4季度走势
每股收益
$2.88+0.00%
近4季度走势
自由现金流
-$2.42B+0.00%
近4季度走势
2026 Q1 财报亮点
核心亮点
Revenue Growth Strong Revenue reached $85.93 B USD for the quarter, marking a solid 5.5% increase over the prior year period.
Gross Profit Surges Gross profit surged to $3.07 B USD, showing a strong 20.1% increase driven by recent acquisitions.
Net Income Improvement Net income attributable to Cencora grew to $559.65 M USD, improving significantly from $488.60 M USD last year.
Operating Cash Usage Down Cash used in operating activities decreased by $0.4 B USD, totaling $2.31 B USD utilized this quarter.
关注风险
Opioid Litigation Liability Accrued litigation liability for opioid settlements stands at $4.3 B USD, payable across the next thirteen years.
Asset Impairment Recorded Management recorded a $165.7 M USD goodwill impairment charge related to the U.S. Consulting Services business sale.
Interest Expense Spikes Net interest expense increased substantially by 159.2% due to significant new debt issuance for acquisitions.
Geopolitical Uncertainties Remain Exposure remains high regarding geopolitical uncertainties, macroeconomic shifts, and potential supply chain disruptions globally.
前瞻展望
OneOncology Acquisition Closed The company finalized the majority acquisition of OneOncology for approximately $4.6 B USD cash in February 2026.
New Segment Reporting A new business reporting structure aligning with growth priorities was implemented starting in the first quarter of fiscal 2026.
Credit Facility Expanded The Multi-Currency Revolving Credit Facility was amended, increasing total commitments available up to $5.5 B USD.
Quarterly Dividend Raised Anticipating continued capital needs, the Board increased the quarterly common stock dividend by 9% to $0.60 USD.
同行对比
营业收入 (TTM)
$397.96B
$325.78B
$244.49B
毛利率 (最新季度)
89.3%
85.0%
78.3%
关键指标
股票代码 | 市值 | 市盈率 (TTM) | 净资产收益率 (TTM) | 负债率 |
|---|---|---|---|---|
| MCK | $114.95B | 26.4 | -245.3% | 10.2% |
| REGN | $79.48B | 17.5 | 14.8% | 6.7% |
| COR | $69.89B | 42.9 | 101.4% | 10.1% |
长期趋势
近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
4.4%
温和增长
4季度净利润复合增长率
-8.0%
盈利能力下滑
现金流稳定性
75%
现金流波动较大
深度研究
下次财报:2026年5月5日
每股收益:-
|营业收入:-
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据